Moffitt logo
Search

Choose a type to search within:

All Doctors Clinical Trials Researchers
search icon

COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More

Clinical Trials Search

Advanced Search

Back to Search Results

Clinical Trial 20402

Cancer Type: Thoracic
Study Type: Treatment
NCT#: NCT04025879

Phase: Phase III
Prinicipal Investigator: Jhanelle Gray

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer

Summary

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

Objective

Primary Objective: To compare the event-free survival (EFS) by blinded independent central review (BICR) in Arm A vs Arm B participants Secondary Objectives: To compare the overall survival (OS) in Arm A vs Arm B participants To assess the pathologic complete response (pCR) rate by BIPR in Arm A vs Arm B participants To assess the major pathological response (MPR) rate by BIPR in Arm A vs Arm B participants Exploratory Objectives: To assess objective response rate (ORR) by BICR in Arm A vs Arm B participants To assess time to death or distant metastasis (TTDM) by BICR in Arm A vs Arm B participants To assess the feasibility of surgery and rate of peri- and post-operative complications (within 90 days of surgery) in Arm A vs Arm B participants To assess safety and tolerability in Arm A vs Arm B participants To assess changes in disease-related symptoms and impacts on health-related quality of life in Arm A vs Arm B participants To assess changes in health status and health-related quality of life To assess changes in physical function To characterize participant perceptions of the bothersomeness of symptomatic AEs Assess the measurement properties of the NSCLC-SAQ To characterize the immunogenic potential of nivolumab To characterize PK of nivolumab To evaluate the efficacy after next line of treatment To evaluate candidate predictive biomarkers including, but not limited to, biomarkers within the tumor (e.g. tumor inflammatory gene expression signatures, driver mutations, immune cell infiltrates, etc) as well as within the periphery (eg, ctDNA, soluble inflammatory /immunosuppressive factors, as potential predictive biomarkers of efficacy)

Treatments

Therapies

Medications

Alimta (Pemetrexed); BMS-936558 (Nivolumab); Nivolumab (Opdivo); Paraplatin (carboplatin); Pemetrexed (); Placebo (); Taxol (paclitaxel); Taxotere (docetaxel); carboplatin (); cisplatin (); docetaxel (); paclitaxel ()

Inclusion Criteria

  • Participants with suspected or histologically confirmed Stage IIA (> 4 cm) to IIIB (T3N2) non-small cell lung carcinoma (NSCLC) with disease that is considered resectable
  • No brain metastasis
  • Treatment-naive for NSCLC (no prior systemic anti-cancer treatment)
  • Ability to provide surgical or biopsy tumor tissue for biomarkers. All participants must have tissue submitted to a central laboratory during screening. Either FFPE (preferred) tissue block or 5-10 unstained tumor tissue slides, obtained within 3 months prior to enrollment, with an associated pathology report, must be submitted to the central laboratory for inclusion. Biopsy should be excisional, core needle, or surgical specimen. Fine needle aspiration is unacceptable for submission. The central laboratory must provide IRT with PD-L1 status prior to randomization.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of > Other protocol-defined inclusion/exclusion criteria apply

    • Exclusion Criteria

  • Participants with an active, known or suspected autoimmune disease
  • Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV)
  • Any previous anti-cancer treatment including cytotoxic, IO treatment, targeted agents, or radiotherapy for NSCLC
  • Prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Other protocol-defined inclusion/exclusion criteria apply

    • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

    Back to top

    ;